SCHEMBL30396372

SCHEMBL30396372

COC(=O)c1cc2cc(Br)ccc2c(=O)n1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.38
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
GSK3B P49841 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
NR1H2 P55055 3/20 0.38
CHEK1 O14757 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
BACE1 P56817 2/20 0.36
MAPK8 P45983 2/20 0.35
NR4A2 P43354 1/20 0.34
MCL1 Q07820 1/20 0.34
PTGS2 P35354 1/20 0.34
KRAS P01116 1/20 0.34
NCEH1 Q6PIU2 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23956770 1.00 USP30 (0.38) USP30CCNB2CDK1CCNB1GSK3B
SCHEMBL19964584 0.91 USP30 (0.40) USP30CCNB2CDK1CCNB1GSK3B
SCHEMBL1201914 0.84 ALDH1A1 (0.49) NR1H2
SCHEMBL4599238 0.84 MCL1 (0.45) USP30CCNB2CDK1CCNB1GSK3B
SCHEMBL30853473 0.84 ALDH1A1 (0.49) NR1H2
SCHEMBL3371321 0.81 USP30 (0.49) USP30CCNB2CDK1CCNB1GSK3B
SCHEMBL30071461 0.81 USP30 (0.49) USP30CCNB2CDK1CCNB1GSK3B
SCHEMBL25190867 0.77 NR1H2 (0.34) NR1H2
SCHEMBL30023439 0.76 ATR (0.36) USP30NR1H2LMNA
SCHEMBL23930133 0.76 ATR (0.36) USP30NR1H2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486251-B2 CBP/EP300 inhibitor and use thereof PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2025-12-02 US disclosed
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF EP300, CREBBP, BPTF USP30 1004/4885CCNB2 3751/4885CDK1 2593/4885
US-12486251-B2 CBP/EP300 inhibitor and use thereof EP300, CREBBP, BPTF USP30 1004/4885CCNB2 3751/4885CDK1 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.